< previous page page_261 next page >

Page 261
9
Changes in Pharmacokinetics and Drug Metabolism Responsibility in Drug Discovery and Development
Peter G. Welling
Parke-Davis Pharmaceutical Research
Warner-Lambert Company
Ann Arbor, Michigan
6fb6ffc4153cdc534470145c4eef46f0.gif
I. Introduction
262
6fb6ffc4153cdc534470145c4eef46f0.gif
II. Interdisciplinary Interactions
263
6fb6ffc4153cdc534470145c4eef46f0.gif
III. The Dynamics of Change
263
6fb6ffc4153cdc534470145c4eef46f0.gif
IV. The Current Situation
264
6fb6ffc4153cdc534470145c4eef46f0.gif
A. Clinical Pharmacology
267
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Clinical Development
267
6fb6ffc4153cdc534470145c4eef46f0.gif
V. The Need for Change, Rationalization, Efficacy, and Economy
270
6fb6ffc4153cdc534470145c4eef46f0.gif
A. Prospective Planning
271
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Discovery
272
6fb6ffc4153cdc534470145c4eef46f0.gif
C. Nonclinical Development
272
6fb6ffc4153cdc534470145c4eef46f0.gif
D. Clinical Pharmacology and Clinical Pharmacokinetic Studies
273
6fb6ffc4153cdc534470145c4eef46f0.gif
E. Clinical Development
275
6fb6ffc4153cdc534470145c4eef46f0.gif
VI. Summary and Conclusions
276
6fb6ffc4153cdc534470145c4eef46f0.gif
References
278

 
< previous page page_261 next page >